The List of Reviewers lists all present, whether permanent or temporary, to provide the full scope of expertise present on that date. Lists are posted 30 days before the meeting and are tentative, pending any last minute changes.
The membership panel is a list of chartered members only.
- Molecular and cellular mechanisms of genetic disease pathogenesis at the level of: gene expression; epigenetic modifications; RNA metabolism; protein structure function; protein synthesis, post-translational modifications, folding and trafficking; metabolic and signaling pathways; regulatory networks.
- Development of genetic disease therapies: cellular and gene therapies; transfer, replacement and correction of genes; changes of gene expression through silencing or activation, e.g., by targeted recruitment of transcription activators/ repressors/ epigenomic modifiers; interventions (including small molecules) altering protein function, e.g., folding or post-translational modifications, enzyme replacement and substrate reduction therapies.
- Development of resources for mechanisms and therapies of genetic diseases: stem cells, nucleic acid transfer vectors, and animal models of human diseases.
- Preclinical and initial clinical studies of genetic disease therapies.
Shared Interests and Overlaps
Genetics of Health and Disease (GHD) Applications focused on Mendelian gene discovery with complex genetic or genomic methods may reviewed by GHD; genetic and genomic studies of Mendelian disease pathogenesis may be reviewed by TAG.
Gene and Drug Delivery (GDD) Applications focused on developing gene delivery methods may be reviewed by GDD; applications focused on gene therapy may be reviewed by TAG.
Molecular Neurogenetics (MNG) Applications focused on the neuroscience context of rare diseases may be reviewed by MNG; studies focused on molecular mechanisms of pathogenesis of rare diseases with neurological pathology may be reviewed by TAG.
Other neuroscience study sections may review applications focused on molecular neurology of rare diseases; applications focused on the molecular mechanisms of neurological pathogenesis and therapies for rare disease may be reviewed by TAG.
Other organ disease focused study sections may review applications studying pathogenesis and treatments for rare diseases related to their respective organ; TAG reviews applications focused on molecular pathogenesis and therapies of rare diseases as multi-organ diseases.